Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223333 · ClinicalTrials.gov registry record · Phase 1

A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers

A Phase 1 study of Type 2 Diabetes, sponsored by AdipoPharma.

Recruiting
Registry status
Phase 1
Development phase
56
Enrollment target
2
Study locations

NCT07223333 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by AdipoPharma. The registered enrollment target is 56 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223333, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by AdipoPharma.

RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG PATAS Trifluoroacetate

Study Locations (2)

Ohio

  • Medpace Clinical Pharmacology Unit - Cincinnati
  • Medpace Clinical Pharmaology Unit - Cincinnati

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2026-01-27
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

AdipoPharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07223333

The ClinicalTrials.gov registry entry for NCT07223333 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is AdipoPharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07223333 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07223333 about?

NCT07223333 is a clinical study titled "A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers". The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.

What is the current status of trial NCT07223333?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2026-01-27. Estimated completion is 2026-09-30.

What conditions does trial NCT07223333 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT07223333?

The interventions under investigation include: Placebo (DRUG), PATAS Trifluoroacetate (DRUG).

Who is sponsoring clinical trial NCT07223333?

This trial is sponsored by AdipoPharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223333 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.